Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2004

View Archived Issues

Stevioside found safe and effective in mild essential hypertension

Long-term budesonide found cost-effective in mild persistent asthma of early onset

New GABA-A modulators for anxiety, convulsions, cognitive disorders, etc.

Amgen patent covers COX-2 inhibitors and their use in inflammation and pain

Pharmacia scientists describe novel fluorinated LXR modulators

New PPARalpha agonists discovered by Kyorin researchers

Novel NK1 antagonists in early development at Kyorin

GSK scientists present new 5-HT receptor antagonists with antipsychotic activity

Novel VR1 antagonists with analgesic activity developed at Amgen

Seroquel receives FDA approval for bipolar-associated mania

Actilon enters phase I for chronic HCV

Pipeline progress report from Tularik

Salix launches Azasan

Initial dosing completed in phase I trial of MRE-0094

Nexium i.v. completes European MRP

Exelixis reviews development pipeline

Australian Cancer Technology expands pipeline with European and U.S. focus

Isis identifies SARS antisense drug candidates

Aastrom Biosciences evaluates Tissue Repair Cell product for tibial fractures

SB-715992 enters broad phase II program for cancer

Dosing commenced in phase II adult AML trial of clofarabine

Letrozole reduces the need for gonadotropins in infertile women undergoing IUI

Magnesium intake and risk of type 2 diabetes in healthy adult women

Improved control of CINV found after adding aprepitant to standard antiemetic regimen

NIP-222, a novel PPARgamma agonist for diabetic nephropathy

Small molecule CCR5 inhibitor tested against SIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...